← Back to headlines
Ultragenyx (RARE) Shares Positive Results from DTX301 Phase 3 Study
Ultragenyx (RARE) has announced positive results from its DTX301 Phase 3 study, marking a significant development for the company's therapeutic pipeline.
1 Apr, 09:35 — 1 Apr, 09:35
Sources
Showing 1 of 1 sources
